A total of 24 new drugs were newly listed or expanded reimbursement standards by this month, improving patient accessibility.

Among new drugs that were already listed, reimbursement standards for 4 products were extended, improving coverage. Although only 10,000 patients in Korea will benefiting from the extension, the result could be interpreted as a result of Korean society’s effort to flexibly expand accessibility to drugs in recognition of the social importance of each drug.

The government estimates around 104,849 patients will be benefiting from the new drugs. By fiscal scale, this will roughly translate to ₩177.9 billion’s worth of coverage reinforcement every year.